Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
This study aims at evaluating efficacy and safety of quadruple therapy (bismuth,
metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin,
clarithromycin and omeprazole: OAC) in H. Pylori eradication. It is hypothesized that
quadruple therapy will be comparable in efficacy to triple therapy. Subjects with confirmed
H. pylori positive status will be randomized to one of the treatments described above. At
week 6 and 10 follow-up visits, a urea breath test(UBT) will be performed to confirm
Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori
The purpose of this study is to evaluate the effect of Pylera when given twice a day. Pylera
approved treatment schedule is 3 pills taken 4 times daily, in addition to omeprazole given
twice daily. In this trial, subjects with confirmed Helicobacter Pylori infection will
receive Pylera treatment and omeprazole twice daily.
H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study
The University of Texas Health Science Center, Houston
The proposed open-label one arm before-after clinical trial will assess the efficacy of a
14-day quadruple therapy containing 420mg of bismuth subcitrate potassium, 375mg of
metronidazole, 375mg of tetracycline hydrochloride (Pylera® packs from Axcan Pharma) and
20mg of omeprazole in eradicating H. pylori infection in 50 asymptomatic adults in El Paso,
Texas. As part of the study we will obtain specimens for culture of H. pylori in a reference
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.